Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
Arcturus Therapeutics (ARCT) Tops Q1 EPS by 338c
May 9, 2022 5:04 PM EDTArcturus Therapeutics (NASDAQ: ARCT) reported Q1 EPS of $1.94, $3.38 better than the analyst estimate of ($1.44). Revenue for the quarter came in at $5.24 million versus the consensus estimate of $6.3 million.
For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.
... More